LOS ANGELES, Nov. 10, 2005 (PRIMEZONE) -- BiomedDiscoveries.com,
http://www.BiomedDiscoveries.com, the online source for
exclusive investor information in the biotechnology sector,
today announced the availability of a new audio interview
with Arc Rajtar, Chief Technology Officer of MIV Therapeutics
(OTC BB:
MIVT.OB -
News); (FWB:MIV), a leading developer of new generation
biocompatible coatings and advanced drug delivery systems.
In the interview, Mr. Rajtar discussed recently announced
interim findings of an independent, long-term animal study
of MIVT's novel technology to create new, highly biocompatible
and bio-friendly coatings for vascular stents, including
drug-eluting stents and other medical devices. Stents are
widely used medical devices designed to prop open clogged
blood vessels to maintain healthy blood flow to the heart
and throughout the body, but current products are associated
with a number of undesirable effects that result from insufficient
biocompatibility.
``Our objective was to develop a coating which will be as
biocompatible as possible and biologically safe,'' said Mr.
Rajtar. ``The results from 1-month and 3-month long arms
of this study confirmed our earlier expectations of superb
biocompatibility and total safety of our Hydroxyapatite
coatings.''
The final results of the 6 Month long study are expected
next week.
MIVT has developed both ultra-thin as well as thicker, drug-eluting
stent coatings based on a highly biocompatible material
called Hydroxyapatite (HAp). The coatings are being conducted
at the Center for Research in Cardiovascular Interventions
of The Methodist Hospital Research Institute in Houston,
TX. The findings were reported to the scientific community
recently at the Transcatheter Cardiovascular Therapeutics
2005 conference, the field's most important annual conference.
``In its thicker, submicron version which is also highly
porous, we see our HAp coatings as exceptional vehicle for
short-term and long-term drug delivery purposes,'' Mr. Rajtar
said. ``This is exceptional because at the present time there
is no other coating which can match the biocompatibility
of Hydroxyapatite and provide drug eluting capability at
the same time.''
Mr. Rajtar explained that during animal trials, MIVT's stent
coatings did not cause any adverse reactions, including
excessive stenosis (re-clogging of arteries through unwanted
tissue growth), and no thrombus (blood clot), both of which
are growing concerns in connection with the drug-eluting
systems now available for use in the health care marketplace.
The entire streaming audio interview with Mr. Rajtar can
be accessed free of charge by visiting http://www.BiomedDiscoveries.com.
About MIV Therapeutics, Inc.
MIV Therapeutics Inc. is developing a next-generation line
of advanced biocompatible coatings for passive and drug-eluting
application on cardiovascular stents and for application
on broad range of other implantable medical devices. The
Company's ultra-thin coating formulation is designed primarily
to protect surrounding tissue from the chemical interaction
with metal stents. The Company's unique ultra-thin coating
has been derived from a biocompatible material called hydroxyapatite
(HAp) that during in-vivo animal trials demonstrated excellent
safety and superior healing properties pursued by the science
in the field of advanced implantable drug delivery systems.
Hydroxyapatite is a bioactive porous material that makes
up the bone mineral and matrix of teeth. It is widely used
as a bone substitute material and for coating implantable
fixation devices in orthopedic, dental and other applications.
The Company's novel drug eluting technologies based on Hydroxyapatite
provide an attractive alternative solution to polymer-based
drug eluting coatings currently in the stent market. The
Company's drug eluting coating is designed to suit a broad
range of implantable medical devices which may benefit from
a highly customizable drug release profile. MIVT reached
a Collaborative Research Agreement (CRA) with the University
of British Columbia and supported a research and development
grant from the Natural Sciences and Engineering Research
Council of Canada (NSERC) in 2002 for the development of
Hydroxyapatite as a drug eluting coating. In December 2004
MIVT received a Government grant for the research program
titled ``Development of Novel Drug Eluting Composite Coatings
for Cardiovascular Stents'' under the National Research Council
-- Industrial Research Assistance Program (NRC-IRAP). Under
this sponsorship the Company will progress to the development
stage, which is expected to finalize the drug-eluting research
and development Program. For more information, please visit
http://www.trilogy-capital.com/tcp/mivt/website.html. To
read or download MIV Therapeutics' Investor Fact Sheet,
visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html.
To obtain daily and historical Company stock quote data,
and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.
MIVT is traded on the Frankfurt, Germany, stock exchange
under the symbol MIV.
Forward-Looking Statements
Except for the historical information contained herein,
the matters discussed in this press release are forward-looking
statements. Such statements are indicated by words or phrases
such as ``believe,'' ``will,'' ``breakthrough,'' ``significant,''
``indicated,'' ``feel,'' ``revolutionary,'' ``should,'' ``ideal,''
``extremely'' and ``excited.'' These statements are made under
``Safe Harbor'' provisions of the Private Securities Litigation
Reform Act of 1995. Actual results may differ materially
from those described in forward-looking statements and are
subject to risks and uncertainties. See the Company's filings
with the Securities and Exchange Commission including, without
limitation, the Company's recent Form 10-K and Form 10-Qs,
which identify specific factors that may cause actual results
or events to differ materially from those described in the
forward-looking statements.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research,
interviews and other information about the smallcap investment
marketplace. BiomedDiscoveries.com strives to provide investors
with information and research-based data regarding important
individual companies and overall marketplace trends. Resources
available on BiomedDiscoveries.com include audio interviews
with corporate leaders and respected commentators, as well
as technical white papers and other forms of market and
investment analysis. It is located at http://www.BiomedDiscoveries.com.
